Natalizumab for Multiple Sclerosis: an observational study related to drug administration, and expectations about benefits and risks

Lara Gatto1, Giovanni Polimeni2, Placido Bramanti2
1CEIS Sanità,University of Rome“Tor Vergata” and University of Catania, Italy
2IRCCS Centro Studi Neurolesi “Bono Pulejo”, Messina, Italy

Background

The emergence of new pharmacological therapies for Multiple Sclerosis (MS) poses some challenges: Natalizumab was approved for the treatment of relapsing-remitting MS in 2004. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4β1 integrin. Natalizumab is administered by intravenous infusion every 28 days, while other therapies were administered daily or 3 times a week. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the blood-brain barrier. Natalizumab has proven effective in preventing relapses, cognitive decline and significantly improving quality of life in people with MS. Despite its efficacy has been confirmed by several clinical trials, the use of Natalizumab has been limited after Progressive Multifocal Leuкоencephalopathy (PML) was identified as a rare but serious brain infection associated with its assumption.

The collection of pharmacovigilance data is essential for monitoring safety of Natalizumab, its effectiveness and patients’ acceptance of risks and expectations of the treatment.

About Natalizumab in Europe in countries (Data of 2009)

Data and methodology

The main objective of the research project has been to monitor all adverse events occurred during the treatment with Natalizumab and to create a Regional registry on the use of Natalizumab for Relapsing Remitting Multiple Sclerosis (RRMS) patients.

All consecutive RRMS patients treated at the six most important neurological centres in Sicily (IRCCS Centro Studi Neurolesi, Policlinico di Palermo “P. Giaccone”, Policlinico di Catania “G. Rodolico”, Policlinico di Messina “G. Martino”, Ospedali Riuniti Villa Sofia-Cervello di Palermo, IRCCS “San Raffaele Giglio” of Cefalù) have been included in the analysis: the Natalizumab patients’ population in Sicily is 280 patients. The project started in the first months of 2012 and, at April 30th, 2012, observations about 107 patients are already available.

A questionnaire has been administered to all patients; they have been asked about their clinical condition, satisfaction with Natalizumab and their acceptance of the risk associated to the treatment.

The questionnaire has been filled by the patients, helped by psychologists and counselors. Some of the questions included in the questionnaire are the MSQol 54 items on daily activities and judgments about their own health.

Moreover, disability status, measured by physicians through the Expanded Disability Status Scale (EDSS), has been collected. Data show a clear picture of the Natalizumab patients’ population (see tables 1 and 2).

Some remarks

Patients’ knowledge about the disease, more than the knowledge about risks of Natalizumab appears to be a relevant factor in determining a positive utility, comparing to other disease modifying drugs (such a interferons). Natalizumab appears to be accepted especially by young patients; there is a negative correlation between the years of disease (and previous treatment) and the positive judgment about Natalizumab.

The assessment of health status before the disease onset (that shows a positive correlation with the dependent variable) as well as the negative correlation with the variable signalling the upper limit of worsening, confirms the positive judgments given by patients to the new therapy, in spite of its risks.

Conclusions

This study represents the preliminary phase of a research started at the end of 2011 and currently being carried in Sicily. At the moment, a network between the main neurological centres dispensing Natalizumab has been established. The descriptive analysis reported here shows patients’characteristics and their first assessment of Natalizumab. The most of patients declare themselves satisfied with the treatment, mainly because of the absence of collateral effects. Patients are, overall, well informed about risks of Natalizumab and about the course of the disease.

References


The explanatory variables concern patients’ clinical situation (age, number of relapses, years of disease) and their perception about their health status before the disease, their knowledge of disease and their beliefs about the higher probability of worsening in the next 5 years.

Since data about knowledge of risks and information about Natalizumab have been collected, a preliminary regression analysis has been run by applying a logit model. Here the dependent variable is the circumstance that the patient declares to receive a positive utility from the treatment (yes/no).

Table 4: A preliminary logit estimation

Lara Gatto, CEIS Sanità –University of Roma “Tor Vergata”, Via Columbia 2, 00133 Rome (Italy)
E-mail: Gatto@CEIS.uniroma2.it, Phone: +39 347 6008789 Fax: 39 090 9284042